JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments * Says commercial license builds on an existing research and ...
Hosted on MSN
Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory
Hazelton confirmed Dyadic expects momentum to build with additional product opportunities in 2025, accelerating in 2026 as the company scales its portfolio and expands its global market reach. He ...
CRISPR Therapeutics' first approval should go on to become massively successful. This approval was a major breakthrough in the area of gene editing. CRISPR Therapeutics has some qualities that could ...
Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...
CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results